thalidomide has been researched along with Pneumonia, Viral in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Pneumonia, Viral: Inflammation of the lung parenchyma that is caused by a viral infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Apremilast is a recently approved drug, belonging to the small molecule phosphodiesterase 4 inhibitors, whose optimal safety and efficacy profile is somewhat affected by slow activity rate in clinical trials." | 5.56 | Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic. ( Atzori, L; Melis, D; Mugheddu, C; Rongioletti, F; Sanna, S, 2020) |
| " Here, we report eight patients with multiple myeloma that underwent immunomodulatory therapies with daratumumab or lenalidomide-based combination treatments and one patient with smoldering multiple myeloma, all of which presented with symptomatic COVID-19." | 3.96 | Outcome of COVID-19 in multiple myeloma patients in relation to treatment. ( Alici, E; Gran, C; Ljunggren, HG; Nahi, H; Susek, KH, 2020) |
| "Apremilast is a recently approved drug, belonging to the small molecule phosphodiesterase 4 inhibitors, whose optimal safety and efficacy profile is somewhat affected by slow activity rate in clinical trials." | 1.56 | Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic. ( Atzori, L; Melis, D; Mugheddu, C; Rongioletti, F; Sanna, S, 2020) |
| "There is no agreed treatment for cytokine storm." | 1.56 | Alternative management of Covid-19 infection. ( Atrah, HI, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 7 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mugheddu, C | 2 |
| Pizzatti, L | 1 |
| Sanna, S | 2 |
| Atzori, L | 2 |
| Rongioletti, F | 2 |
| Armesto, S | 1 |
| González Vela, C | 1 |
| González López, MA | 1 |
| Olisova, OY | 1 |
| Anpilogova, EM | 1 |
| Svistunova, DA | 1 |
| Melis, D | 1 |
| Atrah, HI | 1 |
| Susek, KH | 1 |
| Gran, C | 1 |
| Ljunggren, HG | 1 |
| Alici, E | 1 |
| Nahi, H | 1 |
| Tiscornia, JE | 1 |
| Poggio, TV | 1 |
| Feinsilber, DG | 1 |
| Coleman, AE | 1 |
7 other studies available for thalidomide and Pneumonia, Viral
| Article | Year |
|---|---|
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronavirus Infections; COVID-19; Critical | 2020 |
Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID | 2020 |
Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient.
Topics: Arthritis, Psoriatic; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Care; Humans; Infe | 2020 |
Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronaviru | 2020 |
Alternative management of Covid-19 infection.
Topics: Administration, Intravenous; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatm | 2020 |
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Cohort Stud | 2020 |
Thalidomide Should Be Tested as a Therapeutic Option in COVID-19 Pneumonia.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |